Bimiralisib
- Generic Name
- Bimiralisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F3N7O2
- CAS Number
- 1225037-39-7
- Unique Ingredient Identifier
- 6Z3QHB00LB
- Background
Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).
- Associated Conditions
- -
- Associated Therapies
- -
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- TORQUR
- Target Recruit Count
- 40
- Registration Number
- NCT06319794
- Locations
- π¨π
University Hospital Basel / Department of Dermatology, Basel, Switzerland
π¨πCHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology, Lausanne, Switzerland
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03740100
- Locations
- πΊπΈ
M.D. Anderson Cancer Center, Houston, Texas, United States
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- PIQUR Therapeutics AG
- Target Recruit Count
- 53
- Registration Number
- NCT02249429
- Locations
- π§π¦
University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina
π¬π§Royal Marsden NHS Foundation Trust, London, United Kingdom
π¬π§University College Hospital London, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath